LMR Partners’s Apogee Therapeutics APGE Stock Holding History

LMR Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$842K	–	1505
2026 Q1	$842K	Buy	+10,000	New	+$726K	﹤0.01%	1011

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

LMR Partners's APGE Position: Q2 2026 in Review

LMR Partners increased its Apogee Therapeutics (APGE) stake by 2,190% in Q2 2026, buying an estimated $4M and bringing the position to 46,461 shares worth $6.17M. The position accounts for 0.02% of the portfolio, ranked #575.

LMR Partners first reported a position in APGE in Q3 2025 and has held it in 4 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

LMR Partners held 46,461 shares of Apogee Therapeutics worth $6.17M as of Q2 2026.
LMR Partners bought 44,432 Apogee Therapeutics shares in Q2 2026, an estimated $4M.
Apogee Therapeutics made up 0.02% of LMR Partners's portfolio in Q2 2026, its #575 holding.
LMR Partners first reported a position in Apogee Therapeutics in Q3 2025 and has held it in 4 quarters since.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.